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Prostaglandins (PGs)  I of the E  series  have been shown to inhibit  many in vitro 
measurements of  immune function  in  experimental animals. These include  macrophage 
inhibitory  factor  production  in  guinea  pigs  (1,  2),  direct  cytolysis  in  murine lymphocytes 
(3),  hemolytic plaque  formation by murine leukocytes  (4),  and  mitogen-induced stimula- 
tion of  murine lymphocytes (5).  In the human, Lomnitzer et al. (6) have shown that 
PGEI and PGE2 cause reduction in leukocyte inhibitory  factor  production by phytohe- 
magglutinin(PHA)-stimulated  human lymphocytes. Smith  et  al.  (7)  demonstrated  signif- 
icant  inhibition  of  [3H]thymidine incorporation  into  PHA-stimulated  human lymphocytes 
by PGEI, E2, At, and F~. As in  the  study  by Lomnitzer, the final  concentration  of  PGs 
was relatively  high,  I0-~-I0-4M.  Ferraris  and Derubertis have reported (8)  that  stimu- 
lation  of 10  ~  human luekocytes with optimal concentrations  of  PHA produced -10-8M 
PGE. 
These data suggest that PGs of  the E series  might act  as endogenous modulators in 
human immune reactions.  PGEI is produced in the mitogen stimulation of human 
leukocytes,  and may in turn inhibit  this  stimulation.  Thus, data are accumulating to 
support  the  hypothesis  of  Bourne et  al. (9)  that  PGs are  important  regulators  of  immune 
function. One troublesome  aspect  of the studies on human leukocytes is the great 
disparity  between the amount of  PGE produced  during  mitogen stimulation  (~10-SM or 
5 ng/ml) and the amount required to suppress mitogen stimulation when added to 
cultures  (~10-5M or 5 pg/ml). 
In  the  present  paper  we  describe  the  effects of lower,  more  physiologic 
concentrations of PGs  on  mitogen  stimulation  of human lymphocytes and 
lymphocyte subpopulations.  We  also  describe  the  effect of PG  synthetase 
inhibitors on mitogen-induced stimulation of these cells.  We have identified a 
population of glass adherent mononuclear cells that suppress T-cell mitogenic 
activity through production of PGs of the E series. 
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Materials and Methods 
Subjects.  25  young adult men and women were used as blood donors for the studies. Most 
were studied more than once, and a few were used more than 10 times over the course of several 
months. 
Preparation  of Lymphocytes.  Peripheral  venous  blood  was  drawn  in  syringes  containing 
preservative-free heparin. Mononuclear cells were isolated by centrifugation over Ficoll-Hypaque 
and were washed three times with phosphate-buffered saline (PBS). 
Removal  of Glass  Wool  Adherent  Cells.  Glass  wool  (Pyrex  wool;  Corning  Glass  Works, 
Coming,  N.  Y'.) Was  packed to  8  ml  in  10-ml plastic syringes and equilibrated with  Hanks' 
balanced salt solution (HBSS) supplemented with 10% fetal calf serum (FCS; Grand Island Bio- 
logical Co., Grand Island, N.  Y.). 5 ml of a  cell suspension (5  ×  10  ~ cells) was incubated on the 
column at 37°C for 30 min, then eluted with 30 ml of warm HBSS and washed (10). The yield of 
nonadherent cells was generally 50% with >  95% viability as measured by trypan blue exclusion. 
In some experiments, the cells and the column were equilibrated and eluted with PBS without 
HBSS or FCS. 
Recovery of Glass Adherent Cells.  After elution of the nonadherent cells with HBSS, 10 ml of 
10 -4 M ethylenediamine-tetraacetate (EDTA) in PBS was added, and the columns were incubated 
for an additional 30 min. The cells were then eluted with 30 ml cold PBS with gentle agitation of 
the glass wool and were washed three times in HBSS. The recovery of  the adherent cell population 
was genera!ly 20-30%  of the cells initially put on the column, with >90% viability as measured 
by trypan blue exclusion. 
The percentage of monocytes in the various cell fractions was  as  follows: peripheral blood 
mononuclear cells,  20-40%;  glass nonadherent cells,  <  4%;  and glass adherent cells,  20-40%. 
Wright's stain  of both  the  glass  adherent and  glass  nonadherent populations revealed  100% 
mononuclear cells, with no identifiable platelets. Wright's stain of the peripheral blood mononu- 
clear cell preparations revealed 96-98%  mononuclear cells, 2-4% polymorphonuclear leukocytes 
and  variable  numbers of  platelets.  Previous  work  in  our  laboratory  has  demonstrated  no 
difference between the adherent and nonadherent population in percentage of cells bearing Fc 
receptors, C3 receptors, surface immunoglobulin, or cells forming E-rosettes with sheep erythro- 
cytes (11). 
Preparation of Enriched T-Lymphocyte Suspensions.  Enriched T-cell suspensions were pre- 
pared by the passage of lymphocytes over double-layer (antihuman IgG-IgG) columns composed 
of coated Degalan V-26 plastic beads (Degussa Wolfgang, A. G., Hannau am Main, Germany). 
The preparation of such columns has been previously described (12).  The effluent contained > 
90% lymphocytes which formed E-rosettes with sheep erythrocytes (13) and  <  1% of cells with 
surface immunoglobulin or receptors for IgG (14). 
Drugs.  PG A1, El, E2,  F~a,  and F2a were a  gift of Dr.  John Pike (Upjohn Co.,  Kalamazoo, 
Mich.); indomethacin was a gift of Dr. Clement Stone (Merck Sharp & Dohme, West Point, Pa.); 
and  D,1-6-chloro-a-methyl-carbozole-a-acetic  acid  (RO-20-5720)  was  a  gift  of Dr.  W.  E.  Scott 
(Hoffmann-La Roche Inc.,  Nutley,  N.  Y.).  RO-20-5720  is  an  experimental drug  developed at 
Roche Laboratories, the only known action of which is reversible inhibition of PG synthetase 
(15). All'drugs were dissolved in 95% ethyl alcohol (ETOH)  at 10 mg/ml and diluted with PBS. 
This resulted in  final concentrations of 0.01%  ETOH  in  the cultures.  ETOH  concentration of 
0.0001-0.2%  had no effect on control cultures. 
Cell  Cultures.  The  various  lymphocyte preparations were  cultured  in  minimal  essential 
media (Microbiological Associates, Bethesda, Md.)  supplemented with L-glutamine, penicillin- 
streptomycin, and 20% FCS.  Dose-response curves to PHA (Difco  Laboratories, Detroit, Mich.), 
concanavalin A  (Con A,  Sigma Chemical Co.,  St.  Louis,  Mo.)  and pokeweed mitogen (PWM; 
Grand  Island  Biological  Co.)  were obtained,  and  all  further experiments were performed at 
optimal concentrations of the three mitogens. Cells were cultured in microtiter plates, 1  x  105 
cells in 200 ~l. Mitogens and drugs were added directly to the wells. The final volume in all the 
cultures was adjusted to 240  ~1.  Cells were incubated at 37°C in 5% CO2 for 72 h. The cultures 
were pulsed with [~H]thymidine (New England Nuclear, Boston, Mass.; 5 ×  10 -~ Ci per well) at 
48 h  and harvested on~ glass wool filters at 72 h using a  Mash II Harvester (Valeor Engineering 
Corp., Kenilworth, N. J.). The filters were counted in a liquid scintillation counter. All cultures 
were performed in sextuplicate. Percent inhibition of [3H]thymidine incorporation caused by PGs 
was calculated by dividing the net counts per minute of the mitogen cultures with PG by the net Z 
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Fro.  1.  Percent inhibition of optimal PHA (10 ttg/ml) response ofunfractionated lympho- 
cytes caused by PGA, El, E2, F~, F~ at various concentrations. 
counts per minute of the mitogen cultures without PG. That fraction was expressed as a  percent 
and subtracted from 100% to obtain percent inhibition. Net counts per minute were calculated as 
counts per minute of cells plus mitegen plus drug  (PG,  indomethacin, RO-20-5720,  or nothing) 
minus counts per minute of cells plus drug. 
The Con A-activated suppressor cell was prepared in a  manner similar to that described by 
Shou et al.  (16).  Suspensions of mononuclear cells,  2  ×  10e/ml in minimal essential media and 
20% FCS, were cultured for 18 h with or without the presence of Con A (20/xg/ml). The cells were 
then harvested, washed, treated with mitomycin C, and washed an additional four times in PBS. 
These  Con  A-,  mitomycin  C-pretreated  lymphocytes  were  then  added  to  Con  A-stimulated 
cultures  of  freshly  prepared  lymphocytes  from  the  same  or  different  donors.  The  percent 
inhibition of [aH]thymidine incorporation caused  by the  Con A-activated cells was  calculated 
from the formula of Shou et al.:  (1  -  [(C  c~  -  Cc~)/(CM  -- C)])  ×  100%,  where C cA  is counts per 
minute of normal lymphocytes plus Con A-,  mitomycin C-pretreated cells plus mitogen; C cA  is 
counts  per  minute  of normal  lymphocytes  plus  Con  A-,  mitomycin  C-pretreated  cells;  C~  is 
counts per minute of normal lymphocytes plus mitomycin C-pretreated cells incubated without 
Con A, plus mitogen; C  is counts per minute of normal lymphocytes plus mitomycin C-treated 
cells incubated without Con A. 
To determine whether the Con A-activated suppressor cell acted via PG production, we added 
indomethacin (1 gg/ml) to the second incubation and measured the effect on percent inhibition. 
All cultures were performed in sextuplicate. 
Measurement of PGE Production in Cultures.  The various cell suspensions were prepared as 
described above and were incubated in 1-ml aliquots (5  ×  105 cells/ml) with PHA (10 gg/ml) and 
in some cases,  indomethacin (1  /xg/ml). At 48 h  the cell suspensions were centrifuged and the 
supernates assayed for PGE2 concentrations. The extraction procedures and the radioimmunoas- 
say techniques have been previously described (17).  The assays were done on duplicate samples. 
Results 
Effect of PGs on PHA- and PWM-Stimulated [~H]Thymidine Incorporation 
in Peripheral Mononuclear Cells.  The effects of PGA1,  El, E2,  Fla, and F2a 
on PHA- and PWM-induced [3H]thymidine incorporation in peripheral blood 
lymphocytes are shown in Figs. 1 and 2. Data given are from one representative 
experiment.  Similar  results  were  obtained  with  two  other  normal  donors. 
Small concentrations of PGE~ and E2 (3  ×  10  -s M) inhibited PHA stimulation 
of mononuclear cells, whereas PGs had little effect on PWM stimulation until 
100-fold  greater  concentrations were  used.  The  effect of PGE~  on  PHA  and 
PWM stimulation in 15 normals is shown in Fig. 3. PHA-induced [3H]thymidine 1722  PROSTAGLANDIN-PRODUCING  SUPPRESSOR  CELLS 
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FIG.  2.  Percent inhibition of optimal PWM (50 ~g/ml) response ofunfractionated lympho- 
cytes caused by PGA, El, E2, F1,, Fh at various concentrations. 
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FIG.  3.  Percent inhibition of optimal PHA  (10 ~g/ml) and PWM  (50 izg/ml) response of 
unfractionated lymphocytes caused by PGE~.  Each point represents the mean  +_ SEM  of 
data from 15 individuals. Inhibition is significantly greater than 0; * indicates P  <  0.001 
and  ®  indicates P  <  0.02. 
incorporation was inhibited by as little as 3  ×  10  -9 M PGE~ (P <  0.02)  with a 
50% inhibition at -10  -7 M. PWM-induced stimulation, however, was inhibited 
only slightly by PGE~, and only at higher concentrations. These experiments 
were done at optimal PHA and PWM concentrations. In similar experiments 
done with three subjects,  we found that PGE1 and PGE2 inhibited Con A(20 
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FIG.  5.  Percent  inhibition of optimal  PWM  (50  ~g/ml) response of T-enriched cells by 
PGA. El, E~, F~, F~. 
Inasmuch  as  PHA  and  Con  A  are  primarily  T-cell  mitogens,  and  PWM 
stimulates both B and T cells in the human (18), these data suggest that PGE1 
and PGE2 inhibit T-cell but not B-cell mitogenic activity. To investigate this 
further,  we  studied  the  effects  of PGs  on  PHA  and  PWM  stimulation  of 
enriched T-cell preparations. These preparations contained >90% T cells by E- 
rosette  assay and  <1%  B  cells by  Fc  receptor  and surface  immunoglobulin 
assay. Representative experiments are shown in Figs. 4 and 5.  In the experi- 1724  PROSTAGLANDIN-PRODUCING  SUPPRESSOR  CELLS 
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FIG.  6.  Effect of PG synthetase inhibitors on optimal PHA (10 ~g/ml) stimulation. Data 
from  one  subject  showing  percent  increase  in  [3H]thymidine  incorporation  at  various 
concentrations of indomethacin and RO-20-5720. 
ments performed with enriched T cells, PGE1 and PGE~ were better inhibitors 
of PHA stimulation than they were with whole lymphocyte preparations (Fig. 
4  vs.  Fig.  1).  The enriched T-cell  preparations  responded less  well to  PWM 
than did the whole lymphocyte  preparations (stimulation index of -20 compared 
to -40),  but they were much more suppressible with PGE1  and PGE2  (Fig. 5 
vs.  Fig.  2).  In all of these experiments, PGF~ and PGF~ had little effect on 
mitogen stimulation, and PGA inhibited only at high concentrations. 
Effect of PG Synthetase Inhibitors In Vitro on Mitogen Stimulation.  Panush 
has reported that indomethacin in vitro inhibits mitogen stimulation of human 
lymphocytes (19), but high and possibly toxic doses of the drug were used (20). 
Because small  amounts of PGs  are produced in mitegen-stimulated cultures 
(8),  we  reasoned  that  in  vitro  blockade  of their  synthesis  might  actually 
increase  mitogen stimulation.  Fig.  6  demonstrates this  phenomenon in  one 
subject with varying concentrations of  two PG synthetase inhibitors: iodometha- 
cin and RO-20-5720. Both drugs enhanced stimulation. The effect of indometha- 
cin was greatest over the range of  0.5-10 ~g/ml, which is the same concentration 
as required to inhibit PG synthetase in vitro (15, 21, 22). In this concentration 
range there was no effect of indomethacin on cell viability after 72-h cultures. 
At higher concentrations, the enhancing effect of indomethacin was diminished, 
presumably because of its known toxicity to human leukocytes at levels of 40 
~g/ml and greater (20, 23). In all subsequent experiments, a final concentration 
of 1 ~g/ml was used. At this concentration, indomethacin produced a 58 _+ 28% 
(mean  _  SD,  P  <  0.001)  increase  in  [3H]thymidine incorporation  in  PHA- 
stimulated lymphocytes from 15  normal men  and women,  aged  20-40  yr.  A 
similar enhancement was seen at suboptimal concentrations of PHA,  but at 
supraoptimal concentrations the effect was diminished (Table I). The magnitude 
of the increase seen with indomethacin did not correlate with the magnitude of 
the base-line PHA stimulation (r  =  0.05, P  >  0.8); that is, the increase caused 
by indomethacin did not vary in relation to the size of  the PHA response. In six 
patients tested, indomethacin enhanced Con A-induced [3H]thymidine incorpo- 
ration in a manner similar to its effect on PHA stimulation (81  --- 45% increase, 
P  <  0.01). GOODWIN,  BANKHURST,  AND  MESSNER 
TABLE  I 
Percent Increase  in [ZH]Thymidine Incorporation  Caused  by 
Indomethacin at Different  PHA Concentrations 
PHA concentra-  Before indomethacin  Increase with indomethacin 
tion 
pg/rnl  cpm  % 
-0-  142  +- 47  70  -+ 48 (P <  0.001) 
2  4,078  +- 5,852  55  ±  46 (P <  0.001) 
10  12,630  -+ 6,448  58  _+  28 (P <  0.001) 
20  13,334  -+ 7,573  46  -+ 28 (P <  0.001) 
50  7,984  +- 7,657  16  -+  16 (P <  0.01) 
Each  point  represents  mean  +_  SD  of  15  subjects.  The  cells  were 
cultured as described in Materials and Methods with or without the 
addition of indomethacin (1  ~g/ml). 
1725 
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FIG.  7.  Effect of PG synthetase inhibitors on PHA stimulation of unfractionated lympho- 
cytes vs. T-enriched or glass nonadherent lymphocytes. Lines connect points representing 
percent increase in PHA (10 ~g/ml) stimulation caused by indomethacin (1 ~g/ml) or RO- 
20-5720 (40 ~g/ml) in a subject's lymphocytes before and after T-cell enrichment or passage 
over glass wool. X, RO-20-5720;  e, indomethacin. 
Indomethacin caused less enhancement of PWM-stimulated peripheral lym- 
phocytes (13  _+  5.5% increase in  10 subjects, P  <  0.01),  as would be expected 
from the data above showing little inhibiting effect of PGs on PWM-stimulated 
unfractionated lymphocytes. 
Studies  Using Cell Fractions.  The effect of indomethacin on PHA stimula- 
tion of subfractions of lymphocytes is  shown  in  Fig.  7.  After passage  of the 
lymphocytes over glass  wool  columns  or after T-cell enrichment by passage 
over IgG anti-IgG-coated Degalan beads, the enhancing effect of indomethacin 
and RO-20-5720  on the mitogen response was greatly reduced. In six subjects 
tested, indomethacin caused an increase in PHA stimulation of 49.8 +_ 20.7% in 
untreated lymphocytes and 0.8  _+  7.2%  (mean  _+  SD) increase in lymphocytes 
depleted of glass  wool  adherent  cells.  With  RO-20-5720  there  was  a  27.8  +_ 
11.3% increase in untreated lymphocytes vs. a  7.4 _+  10.8% decrease after glass 
wool  passage.  In  both  cases  the  differences  in  the  response  of treated  vs. 
untreated lymphocytes were significant with P  <  0.001.  Clearly, the glass wool 1726  PROSTAGLANDIN-PRODUCING  SUPPRESSOR  CELLS 
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FIG.  8.  Effect of readdition of glass adherent cells to glass nonadherent cells on enhance- 
ment of PHA (10 ~g/ml) response caused by indomethacin (1 ~g/ml). The PHA response of 
the unfractionated peripheral blood mononuclear cells increases 50% with indomethacin. 
This enhancement decreases to 2% with the nonadherent cells and then increases with the 
readdition of adherent cells. Total cell number per culture was kept constant at 105 in 240 
~1. 
is removing a  cell population upon which the  PG synthetase inhibitors were 
acting  to  cause  enhancement  of  [3H]thymidine  incorporation.  Depletion  of 
glass wool adherent cells had a variable effect on the base-line PHA stimulation 
without  indomethacin.  In  six  experiments,  optimal  PHA  stimulation  gave 
20,424  _+  11,136 cpm before glass wool adherence and 10,586  _+  3,330 after. In 
four  experiments,  total  counts  per  minute  decreased after removal of glass 
wool adherent cells; in one experiment the counts per minute'increased; and in 
one the counts per minute were unchanged. Thus, passage over glass wool has 
effects other than removal of suppressor cells. 
We  next investigated the  effects of indomethacin on  the  PHA response of 
glass  nonadherent  cells  with  the  readdition  of glass  adherent  cells  to  the 
culture.  Fig.  8  shows  the  results  of such  an  experiment,  demonstrating an 
increasing effect of indomethacin with  increasing numbers of glass  adherent 
cells.  At  an  adherent/nonadherent ratio  of 2/10,  indomethacin increased the 
PHA stimulation by 50%, which was identical to the increase in the unfraction- 
ated lymphs. This experiment was performed three times in different donors 
with similar results. 
These glass wool adherent suppressor cells could be monocytes, B  cells, or 
glass adherent T cells. It is doubtful that either polymorphonuclear leukocytes 
or platelets are involved, because the recovered adherent cell population which 
contains  the  suppressor  cell  does  not  contain  those  blood  elements.  In  an 
attempt  to  further characterize this  suppressor  cell,  we  performed a  linear 
regression to obtain a  coefficient of correlation between the  percent increase 
obtained with indomethacin in a  culture and the percent of monocytes in that 
culture.  There was  no  correlation  (r  =  0.20, P  >  0.5).  We  also  found that 
monocyte depletion performed on glass wool columns or in glass Petri dishes, 
without  calcium  in  the  media,  reduced the  percentage of monocytes in  the 
culture without substantially changing the response to indomethacin. In four 
experiments,  monocytes  decreased  from  27  _  4  (mean  -+  SD)  to  9  ___  4% 
monocytes, whereas the percent increase with indomethacin went from 52  _+  7 GOODWIN,  BANKHURST,  AND  MESSNER 
TABLE II 
Effect of Indomethacin  on the Inhibition of Mitogen Stimulation 
Caused by the Con A-Activated Suppressor  Cell 
1727 
Without in-  With indo- 
Con A pre-  domethacin  methacin %  Experiment  treatment 
% inhibition  inhibition 
cprn  cpm 
1  -  5,421  6,494 
25  32 
+  4,084  4,447 
2  -  8,271  9,037 
21  44 
+  7,562  5,066 
3  -  7,015  26  22,360  26 
+  5,173  16,585 
4  -  5,527  5,882 
25  38 
+  4,130  3,659 
5  -  8,806  12,104 
39  54 
+  5,361  5,521 
6  -  6,564  20,883 
15  14 
+  5,599  17,865 
In experiments 1,  2,  and 3  the  Con A-,  mitomycin C-pretreated cells were 
added  (105 cells/well)  to  Con  A-stimulated cultures  (50  ~g/ml)  of  fresh 
allogeneic  cells  (10  s  cells/well).  In  Experiments 4,  5,  and  6  the  Con  A-, 
mitomycin C-pretreated cells were added to cultures of fresh syngeneic cells. 
Indomethacin (1  ~g/ml) was added to the second incubation. See Materials 
and Methods for details. 
to  41  _+  4%.  This represents  a  67%  decrease  in monocytes with only a  21% 
decrease in  indomethacin stimulation. This  does not rule out the possibility 
that a small subpopulation of monocytes contained the PG-producing suppressor 
cell. 
Comparison  to the Con A-Activated Suppressor  Cell.  Shou et al.  (16) and 
Hubert et al.  (24) have recently described a  human suppressor cell population 
that is activated by preincubation with Con A or PHA and inhibits subsequent 
mitogen,  antigen,  or  mixed  lymphocyte culture  activation of allogeneic or 
syngeneic lymphocytes. To determine whether this Con A-activated suppressor 
cell acted through PG production, we added indomethacin to the cultures in an 
attempt to  block  the  inhibition.  As  seen  in  Table  II,  indomethacin did  not 
significantly alter the percent inhibition caused by the Con A-activated sup- 
pressor cell. Thus, the Con A-activated suppressor cell does not inhibit mitogen 
response via PG production, as does the PG-producing suppressor cell. 
Direct Measurement of PG Production.  We next measured the endogenous 
production of PGs in PiCA-stimulated cultures of unfractionated lymphocytes, 
lymphocytes plus indomethacin, and in glass wool nonadherent lymphocytes. 
As shown in Table III, PHA stimulation of  unfractionated lymphocytes produces 
greater than  10  -8  M  PGE  in  48  h.  Addition of indomethacin to the culture 
decreases PGE production to <20% of control values, and PHA stimulation of 
glass  nonadherent  cells  results  in  PGE  production  equal  to  <10%  of that 
produced in cultures of unfractionated lymphocytes. Thus, the amount of PGE 
produced by PHA stimulation of unfractionated lymphocytes is  in the range 
that inhibits [~H]thymidine incorporation when the PGE is added exogenously, 1728  PROSTAGLANDINoPRODUCING  SUPPRESSOR  CELLS 
TABLE  Ill 
PGE2 Production in PHA Cultures 
Lymphocytes +  indo-  Glass nonadherent cells  Untreated lymphocytes  methacin 
8,472  (2.5  ×  10 -8 M)  1,599  (5  x  10 -9 M)  556  (10 -s M) 
5,018  (1.5  x  10  -~ M)  609  (10 -9 M)  414  (10 -9 M) 
Data is from two experiments, and is expressed as picograms per milliliter. 
Approximate molar concentrations are given in parentheses. 5  ×  105 cells in 1 
ml  media  were  cultured  for  48  h  with  PHA  (10  ~g/ml)  with  or  without 
indomethacin (1  t~g/ml). Results given as mean of duplicate samples. 
TABLE  IV 
Percent Inhibition of PHA Stimulation by PGE2 in Untreated Lymphocytes, 




Untreated lym-  Plus 
phocytes  indomethacin  Nonadherent cells  T-enriched 
3  x  10  -9 M  9.5  +_  9.5  18.3  +_  0.6*  29.0  +- 3.9  43.5  +_  29.0 
3  x  10 -~ M  26.1  _+  12.1  51.6  -+  15.3  52.2  _+  9.2  78.0  -+ 7.9 
3  x  10-7  M  48.9  _+  13.1  70.2  _+  13.9  70.2  _+  10.1  89.3  -+- 3.2 
3  x  10 -6 M  63.3  -+ 8.5  74.7  _+  4.9  80.5  _+  12.1  92.0  +- 0.8 
Data given as mean inhibition - SD. A  total of 12 subjects was studied. Lymphocytes from all 
12 were studied untreated.  Lymphocytes  from each subject were also studied with one of the 
treatments: addition of indomethacin  (four  subjects), nonadherent cells (five  subjects), and T- 
enriched cells  (three subjects). 
* Not  significant.  All  other  points  significantly  different  from untreated  lymphocytes at P  < 
0.01,  by using one-tailed t-test. 
and  the  cells that  are  producing  the  PGE  are  90%  removed by passage over 
glass wool. 
Finally,  we studied what effect removing endogenously produced PGs might 
have on the inhibitory effect of exogenously added PGE2. It was probable that 
endogenously produced  PGs were diluting  the  inhibitory  effect of exogenous 
PGE2, and that when we added PGE2 to a  PHA culture of peripheral lympho- 
cytes,  we were starting  with  an  already  inhibited  culture.  Three  methods of 
decreasing  endogenous  PG production  were tried:  the  removal  of glass wool 
adherent  cells,  removal  of cells  by  IgG-anti-IgG  Degalan  column,  and  the 
addition  of indomethacin  before  the  addition  of exogenous  PGE2.  Table  IV 
shows the effect of these  manipulations  on inhibition  of PHA stimulation  by 
PGE2.  In  all  cases,  the  sensitivity  to  exogenous  PGE2  was  significantly  en- 
hanced.  With  this  data,  we  calculate  that  approximately  10  -8  M  PGE~  is 
required for 50% inhibition of PHA stimulation of human lymphocytes. 
Discussion 
We  draw  several  conclusions  from  the  data  presented  above.  First,  low 
concentrations  of PGE1  and  PGE2  suppress  mitogen  stimulation  of human 
lymphocytes.  Second,  these PGs suppress  mitogen stimulation  of T  cells,  but 
probably not B  cells.  Third,  PGs produced endogenously in  mitogen  cultures 
suppress  [3H]thymidine incorporation by T cells in those cultures.  Fourth,  the GOODWIN,  BANKHURST,  AND  MESSNER  1729 
endogenous PGs appear to be produced by a  subset of mononuclear cells that 
can be depleted by adherence to glass wool or by T-cell enrichment on IgG anti- 
IgG-coated Degalan beads. 
Smith et al. (7) showed that PGs, along with aminophylline and isoproterenol, 
would inhibit PHA stimulation of human lymphocytes. Further work by that 
group  (25), as  well  as  by  others  (9), suggests  that  all  agents  that  inhibit 
mitogen response do so by raising intracellular cAMP. The first section of our 
results is  a  confirmation of their data, the  main difference being that much 
lower concentrations of PGE~  and PGE2 were needed to show inhibition. We 
found consistent reproducible inhibition with PGE~ and PGE2 at concentrations 
of 1  ng/ml  (3  ×  10  -9  M)  and  10  ng/ml  (3  ×  10  -8  M;  Fig.  3  and  Table  IV). 
Inasmuch as these concentrations of PGE are similar to what is produced in 
mitogen cultures of human lymphocytes (8), it is no surprise that PG synthetase 
inhibitors increase mitogen response. The concentration range of PGE2  (1-100 
ng/ml)  that  we  found  inhibitory  in  mitogen  cultures  is  also  the  range  of 
concentrations found in inflammatory fluids (26, 27). 
We have no final explanation for why we found significant inhibition of PHA 
stimulation at PGE~ and PGE2 levels three orders of magnitude lower than the 
concentrations employed by Smith et al.  Berenbaum and his co-workers  (28) 
have shown significant inhibition of PHA response in human lymphocytes by 
10  -~  M  PGE2.  Their  assay  employed unseparated  peripheral  blood.  Higher 
concentrations may have  been  needed  in  their  assay because  of binding  of 
PGE2 to blood elements and plasma proteins (29). 
The  finding that  none  of the  PGs  tested  suppressed  PWM  stimulation of 
peripheral leukocytes except in high concentration is interesting, for it suggests 
that these compounds do not inhibit mitogenic activity in human B  lympho- 
cytes. Greaves et al.  (18) have shown that the responding population to PWM 
stimulation of human spleen cells is predominantly composed of B  cells,  but 
when B cells are removed the T cells respond well. In our experiments when T 
cells were enriched (and B cells depleted) by passage over plastic bead columns, 
the inhibition curves of PGE~ and PGE2 on PWM approached the curves of the 
effects of these compounds on PHA-stimulated cells. There is some evidence in 
animals that PGs affect B-cell function, but there are no data in man (4,  30- 
33).  Further  investigation of PG  effects with  other  mitogens  and  on  B-cell 
subpopulations may clarify this issue. 
We have assumed throughout this paper that the enhancing effect of indo- 
methacin  is  secondary to  inhibition  of PG  synthetase.  We  have  based  this 
assumption on three facts. First, although indomethacin has many actions in 
vitro, the only known action of the drug at the low concentrations (1 ~g/ml) we 
employed is PG synthetase inhibition (34). Second, we obtained a  similar but 
smaller enhancement using RO-20-5720,  an experimental drug entirely unre- 
lated structurally to indomethacin. The only known action of RO-20-5720 is PG 
synthetase  inhibition  (15). It  is  a  competitive  inhibitor  of PG  synthetase, 
whereas  indomethacin is  an  irreversible  inhibitor  (15). We  feel  this  is  the 
reason for the smaller enhancement of PHA stimulation we found with RO-20- 
5720.  The  third  reason  for  assuming that  indomethacin works  through PG 
synthetase inhibition  in  our  assay  system  is  that  we  and  others  (8)  have 
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to suppress  [~H]thymidine  incorporation,  and  that  this  production  of PGE  is 
blocked by the addition of indomethacin  (Table III).  We have also shown that 
the  PGE-producing  cells  are  glass  adherent,  and  that  removal  of the  PG- 
producing  cells  by passage  over  glass  wool results  in  loss  of the  enhancing 
effect seen with indomethacin.  Readdition of glass adherent cells to cultures of 
glass nonadherent  cells restores the enhancing effect of indomethacin. 
Our estimate of PGE~ production is a  conservative one, for it does not take 
into account any possible in vitro metabolism of the PGE2 produced.  We could 
find little data on the stability of PGE2 in this system or any similar systems. 
Endogenously  produced  PGE2  is  stable  in  cultures  of  human  rheumatoid 
synovium (35),  and very unstable when incubated with dog or cat serum (36). 
PGE~  accumulates  over  time  in  mitogen  cultures  of mouse  spleen  cells  (8), 
demonstrating  that  whatever  metabolism  there  may  be  is  slower  than  the 
synthetic  rate.  Further  studies  on  the  time-course  of PGE~  production  and 
stability in cultures of human leukocytes appear warranted. 
One might anticipate  that  removing glass wool adherent  cells, and thereby 
removing the suppressor cells, would result in an enhanced mitogen response. 
We did not find this, however. There has been considerable recent interest in 
the helper effect of monocytes in mitogen responses (37-39). The mechanism of 
this  interaction  is not understood,  but different workers have clearly demon- 
strated that removal of monocytes from mitogen cultures causes depression of 
the  response.  We  feel,  therefore,  that  there  is  a  balance  in  PHA  cultures 
between the helper effects of monocytes and the inhibiting effects of suppressor 
cells. Because they are both removed by glass wool, the PHA stimulation will 
increase or decrease with glass wool adsorption,  depending on which cell type 
is  dominant.  In  normals,  it  appears  that  most PHA cultures  give  decreased 
stimulation  with  glass  wool  adsorption  (37);  that  is,  the  helper  function  is 
dominant.  In  some disease  states,  however,  the  suppressor  cell is  dominant. 
We  have  recently  reported  that  glass  wool  adsorption  of mononuclear  cells 
from six patients with Hodgkin's disease resulted in an increased response to 
mitogens  (40).  PHA-stimulated  cultures  of  Hodgkin's  disease  mononuclear 
cells  produced  approximately  fourfold more  PGE2  than  normal.  Blockade  of 
PGE~  production  with  indomethacin  resulted  in  a  182  +_  60%  increase  in 
[3H]thymidine  incorporation  for  the  Hodgkin's  disease  cells  vs.  44  _+  18% 
increase in normals.  After elimination of PG production, either by the addition 
of indomethacin  or  by  removal  of the  glass  adherent  cells,  the  originally 
depressed response to PHA of the Hodgkin's disease cells increased to normal. 
Thus, increased activity of the PG-producing suppressor cell appears responsible 
for the depressed response to PHA in Hodgkin's disease. Preliminary studies in 
our laboratory would indicate that the suppressor cell function is also dominant 
in adult-acquired  agammaglobulinemia  and in the relative anergy of old age. 
The functional role of suppressor cells in the control of the immune response 
has  been  the  subject of intensive  investigation  over the  past  several  years. 
Investigators employing experimental animal models have identified suppressor 
cells that influence many aspects of T- and B-cell function (for review, see 41). 
Furthermore,  T-cell,  B-cell,  and macrophage subpopulations have been impli- 
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These cells have been suggested as etiologic or contributory in the pathogen- 
esis of several diseases,  including  common variable hypogammaglobulinemia 
(43),  IgA deficiency (44),  multiple myeloma (45),  Hodgkin's disease (11, 40, 46), 
and systemic lupus erythematosus (47).  Work in this area has been hindered, 
however,  by  lack  of  a  suitable  assay  of  suppressor  cell  activity.  Human 
suppressor  cell  activity  was  shown  by  adding  circulating  lymphocytes  from 
patients  with  those  diseases  to  normal  lymphocytes  and  demonstrating  an 
inhibition  of various  in  vitro  T-  and  B-cell functional  assays.  More recently, 
several groups have reported on assays for suppressor cell activity in peripheral 
blood leukocytes from normal  humans  (16,  24,  47).  These  assays are  similar 
and involve stimulating normal lymphocytes with Con A for 24 h, then adding 
them to fresh mitogen-stimulated or mixed lymphocyte cultures from the same 
or different donors. The "prestimulated"  cells cause a  20-50% inhibition in the 
subsequent cultures. These Con A-activated suppressor cells inhibit subsequent 
Con A and PHA cultures better than they inhibit PWM cultures (16). Waksman 
and  his  co-workers  (10,  38,  48)  have thoroughly  studied a  similar  system in 
mice and rats and have characterized an inhibitor of DNA synthesis produced 
by Con A-pretreated spleen cells. This is a large molecular weight glycoprotein 
and  appears to mediate the  actions of the Con A-activated suppressor cell in 
the rat and mouse. In this present study, we have shown that the PG-producing 
suppressor cell is clearly different from the Con A-activated cell in humans. 
Although  ours  is  the  first  report  identifying  the  PGs  as  mediators  of 
suppressor  cells  in  humans,  there  is  already  good evidence  that  these  com- 
pounds  function  as  suppressors  in  experimental  animals.  Plescia  et  al.  (33) 
demonstrated that  addition  of syngeneic mouse tumor cells to suspensions  of 
mouse  spleen  cells  inhibited  antibody  response  to  sheep  erythrocytes.  This 
inhibition could be mimicked by addition of PGE2 and blocked by PG synthetase 
inhibitors.  Webb and  Jamieson  (5)  have  described a  mouse,  glass  adherent, 
splenic  cell  that  suppresses  PHA  and  Con  A  stimulation  of the  nonglass 
adherent  population.  This  cell can be neutralized  with  antithymocyte serum 
plus complement,  and its suppression can be blocked by PG synthetase inhibi- 
tors.  Indeed,  this  mouse suppressor cell shares many characteristics  with the 
human  suppressor  cell  described  here.  It  is  glass  adherent;  its  effects  are 
mediated through PG; and it inhibits T-cell function. 
Summary 
Small amounts of PGE inhibit mitogen-induced [aH]thymidine incorporation 
in human peripheral  lymphocytes. The 50%  inhibitory concentration  is  -10  -7 
M,  and  this  is  reduced  to  -10 -8  M  when  endogenous  PGE  production  is 
blocked. PGE inhibits  PHA- and Con A-stimulated cultures much better than 
PWM  cultures,  suggesting  a  differential  effect of PGE  on  T-cell  vs.  B-cell 
function.  In  vitro  blockade  of  PG  synthesis  results  in  -50%  increase  in 
[aH]thymidine incorporation  in PHA cultures.  PGE is produced endogenously 
in PHA cultures by glass adherent suppressor cells. 
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